Changeflow GovPing Healthcare & Life Sciences Dentrifrice Comprising MVE Copolymer, Lactic Ac...
Routine Notice Added Final

Dentrifrice Comprising MVE Copolymer, Lactic Acid, Fluoride

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

USPTO published patent application US20260108434A1 for a dentifrice composition containing a copolymer of MVE with maleic acid (0.9–1.1% by weight), lactic acid or alkali metal salt (1–4% by weight), and a fluoride ion source. The composition is mildly acidic with a slurry pH of 5.0–6.5 and is designed to enhance fluoride uptake into teeth and provide protection against acidic challenges. The application was filed on December 10, 2025, with application number 19414831.

“A dentifrice composition is described comprising a copolymer of MVE with maleic acid; lactic acid or alkali metal salt thereof; and a source of fluoride ions, wherein the copolymer is present in an amount of range 0.9% to 1.1% by weight of the total composition; wherein the lactic acid or alkali metal salt thereof is present in an amount of 1% to 4% by weight of the total composition, wherein the dentifrice composition is mildly acidic, having a slurry pH in the range 5.0 to 6.5.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.

What changed

USPTO published application US20260108434A1 covering a dentifrice composition comprising MVE-maleic acid copolymer, lactic acid or its alkali metal salt, and a fluoride source. The composition ranges specify copolymer at 0.9–1.1% by weight and lactic acid component at 1–4% by weight, with a mildly acidic slurry pH of 5.0–6.5.

Manufacturers and formulators of oral care products should note this published application as competitive intelligence — the specific concentration ranges and pH parameters represent the claimed invention for enhancing fluoride uptake. Inventors listed include Donal Grey, Rachel Taylor, Debbie Hunt, Matthew Hookham, Jonathan Edward Creeth, Shazada Yassar Khan, Richard Lynch, and David Urquhart.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

DENTIFRICE COMPRISING CARBOXYLIC ACID OR ALKALI METAL SALT THEREOF AND A SOURCE OF FREE FLUORIDE IONS

Application US20260108434A1 Kind: A1 Apr 23, 2026

Inventors

Donal GREY, Rachel TAYLOR, Debbie HUNT, Matthew HOOKHAM, Jonathan Edward CREETH, Shazada Yassar KHAN, Richard LYNCH, David URQUHART

Abstract

A dentifrice composition is described comprising a copolymer of MVE with maleic acid; lactic acid or alkali metal salt thereof; and a source of fluoride ions, wherein the copolymer is present in an amount of range 0.9% to 1.1% by weight of the total composition; wherein the lactic acid or alkali metal salt thereof is present in an amount of 1% to 4% by weight of the total composition, wherein the dentifrice composition is mildly acidic, having a slurry pH in the range 5.0 to 6.5. The composition enhances fluoride uptake into teeth and provides protection against acidic challenges.

CPC Classifications

A61K 8/21 A61K 8/365 A61K 8/8164 A61Q 11/00 A61K 2800/591

Filing Date

2025-12-10

Application No.

19414831

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Dentifrice formulation Oral care products
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!